Evenamide 15 mg bid + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Treatment-resistant Schizophrenia
Conditions
Treatment-resistant Schizophrenia
Trial Timeline
Jan 23, 2026 → Sep 1, 2026
NCT ID
NCT07184619About Evenamide 15 mg bid + Placebo
Evenamide 15 mg bid + Placebo is a phase 3 stage product being developed by Newron Pharmaceuticals for Treatment-resistant Schizophrenia. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07184619. Target conditions include Treatment-resistant Schizophrenia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07184619 | Phase 3 | Recruiting |
Competing Products
6 competing products in Treatment-resistant Schizophrenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| MIJ821 Subcutaneous Injection 1 mg + MIJ821 Subcutaneous Injection 4 mg + MIJ821 Subcutaneous Injection 10 mg + Placebo Subcutaneous Injection | Novartis | Phase 2 | 52 |
| MIJ821 + Placebo + Ketamine | Novartis | Phase 2 | 52 |
| Lu AF35700 + Risperidone + Olanzapine | Lundbeck | Phase 3 | 74 |
| Mifepristone 1200 mg daily + Placebo | Corcept Therapeutics | Phase 2 | 47 |
| GH001 + Placebo | GH Research | Phase 2 | 47 |
| VLY-686 + Placebo | Vanda Pharmaceuticals | Phase 2 | 44 |
Other Products from Newron Pharmaceuticals
Safinamide (as add-on therapy) + Safinamide (as add-on therapy) + Safinamide (as add-on therapy)Phase 3
69
Safinamide + Safinamide + PlaceboPhase 3
69
Safinamide + Safinamide + PlaceboPhase 3
69
Safinamide + Safinamide + PlaceboPhase 3
69
Safinamide, MAO-B inhibitor + Safinamide, MAO-B inhibitor + PlaceboPhase 3
69